Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Glucose Transporter Glut1 Double Nickase Plasmid (h): sc-400174-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Glucose Transporter Glut1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Glucose Transporter Glut1 Double Nickase Plasmid (h) and Glucose Transporter Glut1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting SLC2A1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Glucose Transporter Glut1 Antibody (A-4): sc-377228
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Glucose Transporter Glut1 Double Nickase Plasmid (h) | sc-400174-NIC | 20 µg | $410.00 | |||
Glucose Transporter Glut1 Double Nickase Plasmid (h2) | sc-400174-NIC-2 | 20 µg | $410.00 |
SLC2A1 encodes the facilitative glucose transporter GLUT1, a high-affinity transporter that mediates basal glucose uptake across the plasma membrane to sustain glycolysis and oxidative metabolism. GLUT1 activity supports energy homeostasis and redox balance, influencing metabolic reprogramming in proliferative states and adapting cells to hypoxia via HIF-regulated transcriptional programs. As a key determinant of glucose availability, SLC2A1 intersects with AMPK and mTOR signaling through nutrient-sensing feedback and impacts processes such as angiogenesis, blood–brain barrier transport, and immune cell activation. Altered SLC2A1 expression or function is associated with metabolic dysregulation and has been implicated in cancer metabolism and neurological glucose transport defects.
Glucose Transporter Glut1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the SLC2A1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within SLC2A1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt SLC2A1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of SLC2A1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.